Patents Examined by Michael D. Pak
-
Patent number: 6790936Abstract: The invention provides for proteins correlated with cellular resistance to carboxyamido-triazole (CAI) which have at least one Src homology 3 (SH3) binding domain, and functionally equivalent compounds.Type: GrantFiled: November 8, 1999Date of Patent: September 14, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Elise C. Kohn, Lance A. Liotta, Young Sook Kim
-
Patent number: 6114139Abstract: DNA primers effective in screening G protein coupled receptor protein-encoding DNA fragments are provided. The primers which are complementary to nucleotide sequences that are in community with (homologous to) the nucleotide sequences encoding amino acid sequences corresponding to or near the first membrane-spanning domain or the sixth membrane-spanning domain each of known various G protein coupled receptor proteins were designed and synthesized. Methods of amplifying G protein coupled receptor protein-encoding DNAs using the above DNA primers, and novel target G protein coupled receptor protein-encoding DNAs are also provided. Screening of DNA libraries can be efficiently carried out. Human pituitary gland or amygdala-derived and mouse pancreas-derived G protein coupled receptor proteins, etc.Type: GrantFiled: September 14, 1995Date of Patent: September 5, 2000Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Masaki Hosoya, Ryo Fujii, Tetsuya Ohtaki, Shoji Fukusumi, Kazuhiro Ohgi
-
Patent number: 6090778Abstract: A novel growth factor, neurturin, is disclosed. The human and mouse amino acid sequences have been identified. Human and mouse neurturin genomic DNA sequences have been cloned and sequences and the respective cDNA sequences identified. The subcloning into vectors and the preparation of cells stably transformed with the vectors is also disclosed. In addition, methods for treating degenerative conditions using neurturin, methods for detecting gene alterations and methods for detecting and monitoring patient levels of neurturin are provided. Methods for identifying additional members of the neurturin-GDNF family of growth factors are also provided.Type: GrantFiled: December 31, 1996Date of Patent: July 18, 2000Assignee: Washington UniversityInventors: Eugene M. Johnson, Jr., Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe
-
Patent number: 5882873Abstract: The present invention comprises human DNA compositions encoding proteins that confer potassium channel activity to membranes or recipient cell lines. The DNA compositions include structural genes coding for the potassium channel proteins, expression and replication plasmids or vectors containing the structural genes and host cells expressing those genes. Methods of screening compounds for potassium channel modulating activity are also described.Type: GrantFiled: August 9, 1995Date of Patent: March 16, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Michael Jerome Bienkowski, Vincent Edward Groppi, Jr.
-
Patent number: 5879896Abstract: A human receptor protein capable of binding TRH, a DNA coding for said protein, use of the proetein and DNA, a method for preparing said protein, and antibodies to the protein are described.The human TRH receptor protein and the DNA coding for the protein of the present invention are useful as (1) a diagnostic composition for neuropathy (particularly, dementia), (2) a pharmaceutical composition for neuropathy and (3) a material used for screening a TRH receptor agonist or antagonist.Type: GrantFiled: August 9, 1994Date of Patent: March 9, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuji Hinuma, Masaki Hosoya, Haruo Onda
-
Patent number: 5856125Abstract: The present invention relates, inter alia, to the ERF gene and to the products encoded by this gene. More particularly, the present invention relates to DNA sequences encoding ERF and AERF; polypeptides encoded by such DNA sequences; ERF chimeric molecules; and methods of using ERF and ERF chimeric molecules to reduce tumorigenicity in a tumor cell.Type: GrantFiled: June 5, 1995Date of Patent: January 5, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: George J. Mavrothalassitis, Donald G. Blair, Robert J. Fisher, Gregory J. Beal, Jr., Meropi A. Athanasiou, Dionyssios N. Sgouras
-
Patent number: 5849525Abstract: The present invention relates to nucleic acid and amino acid sequences corresponding to a proton-coupled peptide transporter and methods of making and using such transporter.Type: GrantFiled: December 21, 1995Date of Patent: December 15, 1998Assignee: Brigham and Women's Hospital, Inc.Inventor: Matthias Hediger
-
Patent number: 5847089Abstract: The present invention is a biodegradable, reversibly-swellable, polyvalent cation-binding, protein-based hydrogel which comprises an acyl-modified protein matrix in which the acyl-modified protein matrix is crosslinked with a bifunctional crosslinking reagent, and a method of making the same.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: Wisconsin Alumni Research FoundationInventors: Srinivasan Damodaran, Der-Chyan Hwang
-
Patent number: 5843714Abstract: The present invention provides polynucleotides which identify and encode a novel human proteolipid (PLHu). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PLHu. The invention also provides for the use of substantially purified PLHu and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of PLHu. Additionally, the invention provides for the use of antisense molecules to PLHu in the treatment of diseases associated with the expression of PLHu. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding PLHu and antibodies which specifically bind to the protein.Type: GrantFiled: July 26, 1996Date of Patent: December 1, 1998Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Olga Bandman, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 5840844Abstract: DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.Type: GrantFiled: August 10, 1995Date of Patent: November 24, 1998Assignee: Genentech, Inc. University of CaliforniaInventors: Laurence A. Lasky, Steven D. Rosen, Scott E. Stachel, Mark S. Singer
-
Patent number: 5837544Abstract: The present invention is directed to novel chimeric proliferation receptor proteins and DNA sequences encoding these proteins where the chimeric proteins are characterized in three general categories. In one category, the novel chimeric proteins comprise at least three domains, namely, an extracellular inducer-responsive clustering domain capable of binding an extracellular inducer that transmits a signal to a proliferation signaling domain, a transmembrane domain and a proliferation signaling domain that signals a host cell to divide. In the second category, the novel chimeric proteins comprise at least two domains, namely, an intracellular inducer-responsive clustering domain capable of binding an intracellular inducer and a proliferation signaling domain that signals the cell to divide.Type: GrantFiled: June 7, 1995Date of Patent: November 17, 1998Assignee: Cell Genesys, Inc.Inventors: Daniel J. Capon, Huan Tian, Douglas H. Smith, Genine A. Winslow, Miriam Siekevitz
-
Patent number: 5830685Abstract: A novel bronchial or bronchiolar epithelial cell from normal neonatal mammalian lung has been isolated, established and maintained for multiple passages in the absence of serum, without undergoing crisis or senescence. By careful manipulation of the nutritional/hormonal microenvironment we have been able to select, from a heterogeneous population, a single epithelial cell type which can maintain highly differentiated features in vitro. This cell type has characteristics of bronchiolar epithelial cells. A clonal line, RL-65, has been selected and observed for more than 3 years in continuous culture. It has been characterized by ultrastructural, morphological and biochemical criteria.Type: GrantFiled: July 16, 1992Date of Patent: November 3, 1998Assignee: Genentech, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts
-
Patent number: 5830760Abstract: Methods for establishing continuous SCF dependent lympho-hematopoietic progenitor cell lines capable of differentiating into erythroid, myeloid, and B lymphocytic lineages, and GM-CSF dependent neutrophil progenitor cell lines capable of differentiating into neutrophils but not into monocytes, mast cells, or basophils, by introducing into bone marrow, fetal spleen, fetal liver, or other hematopoietic myeloid cells nucleic acid encoding a dominant negative suppressor of a retinoic acid receptor-alpha and a selectable marker, and culturing the recombinant cells in culture medium containing SCF or GM-CSF, agents allowing for selective growth of the recombinant cells, and a level of retinoic acid of less than about 10.sup.-8 M to about 10.sup.-9 M in the case of establishing neutrophilic progenitor cell lines. Addition of a retinol compound induces the latter cell line to differentiate into neutrophils.Type: GrantFiled: January 26, 1996Date of Patent: November 3, 1998Assignee: Fred Hutchinson Cancer Research CenterInventors: Schickwann Tsai, Steven J. Collins
-
Patent number: 5831061Abstract: Unique ecdysis triggering hormone nucleic acid molecules and ETH peptides/proteins having biological activity for promoting ecdysis in insects are disclosed. Methods of preparing the peptides/proteins by recombinant means, and use of the peptide/proteins in an insect controlling agent are also provided. Methods of inducing ecdysis using the sequences encoding the ETH peptides/proteins are outlined. Insecticidal preparations that are specific to insects that shed their skin, and that do not pose an environmental threat to humans or animals, are also disclosed employing the nucleic and molecules and peptides and proteins they encode. Processes employing the ETH nucleic acid encoding sequences to identify ETH receptors are also defined. The ETH receptors are employed in screening assays to select organic molecules capable of binding the ETH receptor and inducing ecdysis and eclosion, particularly in insects.Type: GrantFiled: January 3, 1996Date of Patent: November 3, 1998Assignee: The Regents of the University of CaliforniaInventors: Michael E. Adams, Sarjeet S. Gill, Dusan Zitnan
-
Patent number: 5801015Abstract: The present invention relates to the discovery of novel cell cycle regulatory proteins from the human pathogen Candida.Type: GrantFiled: June 5, 1995Date of Patent: September 1, 1998Assignee: Mitotix, Inc.Inventors: Guillaume Cottarel, Veronique Damagnez, Giulio Draetta
-
Patent number: 5801143Abstract: A cyclic depsipeptide having the general formula (I) ##STR1## (wherein n is an integer of 5-15) or a pharmacologically acceptable salt thereof. The present compound can be prepared by cultivation of a cyclic depsipeptide-producing microorganism belonging to the genus of Bacillus. The present compounds are useful as a therapeutic agent for hyperlipemia, an agent for inhibiting the secretion of lipids or an agent for inhibiting the production of apolipoprotein B.Type: GrantFiled: November 25, 1996Date of Patent: September 1, 1998Assignee: Nisshin Flour Milling Co., Ltd.Inventors: Shigeru Hiramoto, Yukio Saito, Shigeo Hatanaka, Akiko Shingai
-
Patent number: 5792743Abstract: The invention features a method for promoting neural growth in vivo in the mammalian central nervous system by administering a neural cell adhesion molecule which can overcome inhibitory molecular cues found on glial cells and myelin to promote neural growth. Also featured active fragments, cognates, congeners, mimics, analogs, secreting cells and soluble molecules thereof, as well as antibodies thereto, and DNA molecules, vectors and transformed cells capable of expressing them. The invention also includes transgenic mouse lines expressing a neural adhesion molecule in differentiated astrocytes, and cells and tissues derived therefrom. The expression of the neural adhesion molecule enhances neurite outgrowth on central nervous system tissue derived from these transgenic mice. The invention also features methods for enhancing neuronal outgrowth of CNS neurons, for enhancing memory and for increasing synaptic efficacy.Type: GrantFiled: June 7, 1995Date of Patent: August 11, 1998Assignee: Acorda TherapeuticsInventor: Melitta Schachner
-
Patent number: 5763400Abstract: Unique ecdysis triggering hormone nucleic acid molecules and ETH peptides/proteins having biological activity for promoting ecdysis in insects are disclosed. Methods of preparing the peptides/proteins by recombinant means, and use of the peptide/proteins in an insect controlling agent are also provided. Methods of inducing ecdysis using the sequences encoding the ETH peptides/proteins are outlined. Insecticidal preparations that are specific to insects that shed their skin, and that do not pose an environmental threat to humans or animals, are also disclosed employing the nucleic and molecules and peptides and proteins they encode. Processes employing the ETH nucleic acid encoding sequences to identify ETH receptors are also defined. The ETH receptors are employed in screening assays to select organic molecules capable of binding the ETH receptor and inducing ecdysis and eclosion, particularly in insects.Type: GrantFiled: January 3, 1996Date of Patent: June 9, 1998Assignee: The Regents of the University of CaliforniaInventors: Michael E. Adams, Dusan Zitnan
-
Patent number: 5760259Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycotyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.Type: GrantFiled: March 18, 1996Date of Patent: June 2, 1998Assignees: Washington University, Johns Hopkins Univ.Inventors: Jeffrey I. Gordon, George W. Gokel, Paul T. Englund
-
Patent number: 5744324Abstract: Compositions and methods are provided for producing functional mammalian inward rectifier, G-protein activated potassium channels (Kir3.0 channels). A channel is a multimeric protein comprising one or more Kir3.0 polypeptides, e.g. Kir3.1, Kir3.2, etc., where the polypeptides may be from the same or different species. The functional channel has the distinctive features of an anomalous rectifier, in that it conducts inward but not outward K.sup.+ current; it is blocked by low concentrations of extracellular Cs.sup.+ or Ba.sup.2+ ; and the conductance of the channel does not depend solely on voltage, but on (E--E.sub.K). The ability of the channel to conduct inward K.sup.+ current is modulated by G-proteins, particularly G-proteins of the G.sub.i /G.sub.o family. A number of mammalian cell surface receptors activate G-proteins as a consequence of specific ligand binding. The signal transduction from receptor to Kir3.0 channel is therefore coupled through G-protein intermediates.The functional Kir3.Type: GrantFiled: March 7, 1996Date of Patent: April 28, 1998Assignee: California Institute of TechnologyInventors: Henry A. Lester, Norman Davidson, Paulo Kofuji